文献速递肝病

美国COVID-19大流行前后及期间基于病因的肝硬化住院趋势

Trends in aetiology-based hospitalisation for cirrhosis before and during the COVID-19 pandemic in the United States.
PubMed 文献 · Aliment Pharmacol Ther · 2023-05-15

基于美国2019-2020年全国住院样本,分析316,418例肝硬化住院(代表1,582,090例住院)的季度趋势。酒精相关肝病肝硬化住院率显著上升(QPC 3.6%),丙型肝炎肝硬化住院率稳步下降(QPC -1.4%)。COVID-19时期肝硬化院内死亡率更高,酒精相关肝病较丙型肝炎肝硬化院内死亡风险高40%。

要点

  • 酒精相关肝病肝硬化住院率显著上升(QPC 3.6%,95%CI 2.2%-5.1%),COVID-19时期尤为明显。
  • 丙型肝炎肝硬化住院率稳步下降(QPC -1.4%,95%CI -2.5%至-0.1%)。
  • 酒精相关肝硬化较丙型肝炎肝硬化院内死亡风险高40%,COVID-19感染为独立预测因素。

核心结论

  • 肝硬化院内死亡率在COVID-19时期高于COVID-19前时期。
  • 酒精相关肝病是肝硬化院内死亡的首要病因特异性原因,COVID-19感染具有独立的不利影响。

研究设计与样本

  • 基于美国全国住院样本(National Inpatient Sample)2019-2020年的分析,纳入316,418例肝硬化住院,代表1,582,090例肝硬化住院。

主要发现

  • 肝硬化住院在COVID-19时期以相对较高的速率增加。
  • 酒精相关肝病肝硬化住院率显著上升(季度百分比变化QPC 3.6%,95%CI 2.2%-5.1%),COVID-19时期尤为明显。
  • 丙型肝炎肝硬化住院率稳步下降,QPC趋势为-1.4%(95%CI -2.5%至-0.1%)。
  • 酒精相关肝病(QPC 1.7%,95%CI 0.9%-2.6%)和非酒精性脂肪性肝病相关(QPC 0.7%,95%CI 0.1%-1.2%)肝硬化住院比例季度趋势显著上升,而病毒性肝炎稳步下降。
  • COVID-19时期和COVID-19感染是肝硬化及失代偿期肝硬化住院期间院内死亡的独立预测因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Patients with pre-existing cirrhosis and exposure to coronavirus disease-19 (COVID-19) may portend a poor prognosis. We evaluated the temporal trends in aetiology-based hospitalisations and potential predictors of in-hospital mortality in hospitalisation with cirrhosis before and during the COVID-19 pandemic. METHODS: Based on the US National Inpatient Sample 2019-2020, we determined quarterly trends in aetiology-based hospitalisations with cirrhosis and decompensated cirrhosis and identified predictors of in-hospital mortality in hospitalisation with cirrhosis. RESULTS: We analysed 316,418 hospitalisations, representing 1,582,090 hospitalisations with cirrhosis. Hospitalisations for cirrhosis increased at a relatively higher rate during the COVID-19 era. Hospitalisation rates for alcohol-related liver disease (ALD)-related cirrhosis increased significantly (quarterly percentage change [QPC]: 3.6%, 95% CI: 2.2%-5.1%), with a notably higher rate during the COVID-19 era. In contrast, hospitalisation rates for hepatitis C virus (HCV)-related cirrhosis decreased steadily with a trend of -1.4% of QPC (95% CI: -2.5% to -0.1%). Quarterly trends in the proportion of ALD- (QPC: 1.7%, 95% CI: 0.9%-2.6%) and nonalcoholic fatty liver disease-related (QPC: 0.7%, 95% CI: 0.1%-1.2%) hospitalisations with cirrhosis increased significantly but declined steadily for viral hepatitis. The COVID-19 era and COVID-19 infection were independent predictors of in-hospital mortality during hospitalisation with cirrhosis and decompensated cirrhosis. Compared with HCV-related cirrhosis, ALD-related cirrhosis was associated with a 40% higher risk of in-hospital mortality. CONCLUSION: In-hospital mortality in cirrhosis was higher in the COVID-19 era than in the pre-COVID-19 era. ALD is the leading aetiology-specific cause of in-hospital mortality in cirrhosis with an independent detrimental impact of the COVID-19 infection.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Kim D, Perumpail BJ, Wijarnpreecha K, et al. Trends in aetiology-based hospitalisation for cirrhosis before and during the COVID-19 pandemic in the United States. Aliment Pharmacol Ther. 2023. PMID: 37189243. doi:10.1111/apt.17547

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。